Risk adjusted net present value: What is the current valuation of AstraZeneca’s Saruparib?

Saruparib is a small molecule commercialized by AstraZeneca, with a leading Phase III program in Metastatic Prostate Cancer.

Nostrum Laboratories and its CEO — who once defended Shkreli price hikes — to pay up to $50 million over Medicaid rebates

A pharmaceutical company and its chief executive — who once defended Martin Shkreli for raising drug prices to controversial heights — agreed to pay up

November 1, 2023

UK soft drinks levy may have reduced tooth extractions in children by 12%, study finds

The UK soft drinks industry levy introduced in 2018 may have reduced the number of under 18s having a tooth removed due to tooth decay

November 15, 2023

FDA announces recall of heart pumps linked to deaths and injuries

A pair of heart devices linked to hundreds of injuries and at least 14 deaths has received the FDA’s most serious recall, the agency announced

April 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.